Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). METHODS: We conducted a phase 2, single-cohort, 25-center, global study of tisagenlecleucel in pediatric and young adult patients with CD19+ relapsed or refractory B-cell ALL. The primary end point was the overall remission rate (the rate of complete remission or complete remission with incomplete hematologic recovery) within 3 months. RESULTS: For this planned analysis, 75 patients received an infusion of tisagenlecleucel and could be evaluated for efficacy. The overall remission rate within 3 months was 81%, with all patients who had a response to treatment found to be negative for minimal residual disease, as assessed by means of flow cytometry. The rates of event-free survival and overall survival were 73% (95% confidence interval [CI], 60 to 82) and 90% (95% CI, 81 to 95), respectively, at 6 months and 50% (95% CI, 35 to 64) and 76% (95% CI, 63 to 86) at 12 months. The median duration of remission was not reached. Persistence of tisagenlecleucel in the blood was observed for as long as 20 months. Grade 3 or 4 adverse events that were suspected to be related to tisagenlecleucel occurred in 73% of patients. The cytokine release syndrome occurred in 77% of patients, 48% of whom received tocilizumab. Neurologic events occurred in 40% of patients and were managed with supportive care, and no cerebral edema was reported. CONCLUSIONS: In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients with relapsed or refractory B-cell ALL, with transient high-grade toxic effects. (Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT02435849 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some immunotherapies have shown promise in this setting, such as dinutuximab administered in combination with cytotoxic therapy in relapsed/refractory neuroblastoma3,4.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“It has been reported that CAR-T cell therapy shows high response rates to B-ALL patients in different age groups [117–119].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“Any grade 3 or 4 adverse event 19 (25) 33 (44) 8 (11) 4 (6)”
Self-citationLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citationMilone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197 · cited 2×
“Increase in aspartate aminotransferase 5 (7) 2 (3) — —”
BackgroundSelf-citationGardner, R. A., Finney, O., Annesley, C., Brakke, H., Summers, C., Leger, K., Bleakley, M., Brown, C., Mgebroff, S., Kelly-Spratt, K. S., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769208 · Cited by 1,121
von Stackelberg, A., Locatelli, F., Zugmaier, G., Handgretinger, R., Trippett, T. M., Rizzari, C., Bader, P., O’Brien, M. M., Brethon, B., Bhojwani, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3301 · Cited by 614 · cited 1×
“Decrease in neutrophil count 1 (1) 6 (8) 1 (1) 1 (1)”
Self-citationSabatino, M., Hu, J., Sommariva, M., Gautam, S., Fellowes, V., Hocker, J. D., Dougherty, S., Qin, H., Klebanoff, C. A., Fry, T. J., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683847 · Cited by 383
Cited by
Items 401–500 of 1,024
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas
Scarfò, I., Ormhøj, M., Frigault, M. J., Castaño, A. P., Lorrey, S., Bouffard, A. A., Scoyk, A. V., Rodig, S. J., Shay, A. J., Aster, J. C., et al. (2018) · Blood · doi:10.1182/blood-2018-04-842708 · Cited by 149
Immunotherapies and Combination Strategies for Immuno-Oncology
Barbari, C., Fontaine, T., Parajuli, P., Lamichhane, N., Jakubski, S., Lamichhane, P., & Deshmukh, R. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145009 · Cited by 140
Next-generation cell therapies: the emerging role of CAR-NK cells
Başar, R., Daher, M., & Rezvani, K. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002547 · Cited by 155
Engineering-enhanced CAR T cells for improved cancer therapy
Milone, M. C., Xu, J., Chen, S., Collins, M. A., Zhou, J., Powell, D. J., & Melenhorst, J. J. (2021) · Nature Cancer · doi:10.1038/s43018-021-00241-5 · Cited by 156
T cell dysfunction and therapeutic intervention in cancer
Zebley, C. C., Zehn, D., Gottschalk, S. M., & Chi, H. (2024) · Nature Immunology · doi:10.1038/s41590-024-01896-9 · Cited by 158
A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML
John, S., Chen, H., Deng, M., Gui, X., Wu, G., Chen, W., Li, Z., Zhang, N., An, Z., & Zhang, C. C. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.08.001 · Cited by 138
Toxicities of CD19 CAR‐T cell immunotherapy
Hirayama, A. V. V., & Turtle, C. J. (2019) · American Journal of Hematology · doi:10.1002/ajh.25445 · Cited by 152
“B cells, effective CD19 CAR-T cell therapy will be accompanied by B cell aplasia, which can be managed by the periodic administration of intravenous immunoglobulin (IVIG).(2,4,6,9,12,15,45)”
BackgroundZhao, W., Wang, B., Chen, L., Fu, W., Xu, J., Liu, J., Jin, S., Chen, Y., Cao, X.-M., Yang, Y., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01301-8 · Cited by 152
Self-citationPehlivan, K. C., Duncan, B. B., & Lee, D. W. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0470-x · Cited by 153
Alcantara, M., Tesio, M., June, C. H., & Houot, R. (2018) · Leukemia · doi:10.1038/s41375-018-0285-8 · Cited by 150
Self-citationPrecision medicine in acute lymphoblastic leukemia
Pui, C. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0759-8 · Cited by 159
Dickinson, M. J., Barba, P., Jaeger, U., Shah, N. N., Blaise, D., Briones, J., Shune, L. O., Boissel, N., Bondanza, A., Mariconti, L., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1276 · Cited by 158
“org populations, enhance the potency of the product, and increase the scalability of the manufacturing process (4, 12).”
Self-citationSesques, P., Ferrant, E., Safar, V., Wallet, F., Tordo, J., Dhomps, A., Karlin, L., Brisou, G., Vercasson, M., Schwiertz, V., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25951 · Cited by 145
“Platinum-based regimen 4 (12) 2 (7) 6 (9)”
InfluentialAllogeneic CAR Cell Therapy—More Than a Pipe Dream
Caldwell, K. J., Gottschalk, S. M., & Talleur, A. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.618427 · Cited by 151
Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)
Huang, H., Yao, Y., Deng, X., Huang, Z., Chen, Y., Wang, Z., Hong, H., Huang, H., & Lin, T. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5545 · Cited by 152
Cytokine release syndrome: grading, modeling, and new therapy
Liu, D., & Zhao, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0653-x · Cited by 145
Base-edited CAR T cells for combinational therapy against T cell malignancies
Georgiadis, C., Rasaiyaah, J., Gkazi, S. A., Preece, R., Etuk, A., Christi, A., & Qasim, W. (2021) · Leukemia · doi:10.1038/s41375-021-01282-6 · Cited by 150
Wehrli, M., Gallagher, K., Chen, Y., Leick, M. B., McAfee, S. L., El-Jawahri, A. R., DeFilipp, Z. M., Horick, N., O’Donnell, P. V., Spitzer, T. R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003847 · Cited by 147
Recent Advances and Challenges in Cancer Immunotherapy
Peterson, C. M., Denlinger, N., & Yang, Y. (2022) · Cancers · doi:10.3390/cancers14163972 · Cited by 146
“lasting remissions have been demonstrated in pediatrics, but most adult patients require an allogeneic stem cell transplant post CAR19 due to high rates of relapse [75,76].”
BackgroundNext-Generation Cancer Immunotherapy Targeting Glypican-3
Shimizu, Y., Suzuki, T., Yoshikawa, T., Endo, I., & Nakatsura, T. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00248 · Cited by 144
“Development of CAR-T Therapy Targeting Membrane GPC3 While CAR-T therapy has shown a remarkable response rate exceeding 80% against B cell blood tumors (51, 52), fully promising results have not yet been obtained against solid carcinomas, such as glioblastoma (53), pancreatic cancer (54), and prostate cancer (55, 56).”
BackgroundThe Complex Integration of T-cell Metabolism and Immunotherapy
Madden, M. Z., & Rathmell, J. C. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0569 · Cited by 156
“ACT has had promising success in some tumor types, particularly with CD19-specific CAR T cells used against B cell acute lymphoblastic leukemia (B-ALL) and B cell lymphomas, where up to half or more of patients can achieve durable remission[51].”
BackgroundDirect in vivo CAR T cell engineering
Short, L., Holt, R. A., Cullis, P. R., & Evgin, L. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.03.004 · Cited by 155
In the Eye of the Storm: Immune‐mediated Toxicities Associated With CAR‐T Cell Therapy
Borrega, J. G., Gödel, P., Rueger, M. A., Onur, O. A., Shimabukuro‐Vornhagen, A., Kochanek, M., & Böll, B. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000191 · Cited by 144
Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients
Marofi, F., Rahman, H. S., Al-Obaidi, Z. M. J., Jalil, A. T., Abdelbasset, W. K., Suksatan, W., Dorofeev, A. E., Shomali, N., Chartrand, M. S., Pathak, Y. V., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02420-8 · Cited by 144
Jung, I.-Y., Narayan, V., McDonald, S., Rech, A. J., Bartoszek, R. L., Hong, G., Suhoski, M. M., Xu, J., Boesteanu, A. C., Barber-Rotenberg, J. S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn7336 · Cited by 152
Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells
Stein, A. M., Grupp, S. A., Levine, J. E., Laetsch, T. W., Pulsipher, M. A., Boyer, M. W., August, K. J., Levine, B. L., Tomassian, L., Shah, S. S., et al. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12388 · Cited by 146
“Tisagenlecleucel (CTL019) is a CAR- T cell immunotherapy that produces durable responses in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r B- ALL).(2,3) This treatment”
BackgroundSelf-citationCell‐Based Delivery Systems: Emerging Carriers for Immunotherapy
Li, Z., Wang, Y., Ding, Y., Repp, L., Kwon, G. S., & Hu, Q. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100088 · Cited by 146
Wat, J., & Barmettler, S. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.10.037 · Cited by 148
Nicolai, C. J., Parker, M. H., Qin, J., Tang, W., Ulrich-Lewis, J. T., Gottschalk, R., Cooper, S. E., Lopez, S. A. H., Parrilla, D., Mangio, R. S., et al. (2024) · Blood · doi:10.1182/blood.2024024523 · Cited by 148
Global efforts toward the cure of childhood acute lymphoblastic leukaemia
Pui, C., Yang, J. J. J., Bhakta, N. H., & Galindo, C. R. (2018) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(18)30066-x · Cited by 155
Gill, S. I., Vides, V., Frey, N. V., Hexner, E. O., Metzger, S. T., O'Brien, M., Hwang, W., Brogdon, J. L., Suhoski, M. M., Fraietta, J. A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007317 · Cited by 144
Self-citationCAR-T Cell Therapy for Breast Cancer: From Basic Research to Clinical Application
Yang, Y.-H., Liu, J., Lu, C., & Wei, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.70120 · Cited by 143
“In 2017, two CAR-T cell therapies targeting CD19 named tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma) were approved by FDA for treating children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphomas (NHLs), respectively[26-…”
BackgroundArcangeli, S., Falcone, L., Camisa, B., De Girardi, F., Biondi, M., Giglio, F., Ciceri, F., Bonini, C., Bondanza, A., & Casucci, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01217 · Cited by 134
“Moreover, long and individualized manufacturing is not always compatible for patients with high proliferative diseases and advanced stage cancers, due to the possibility of further progressing during the handling procedure (1, 8, 33, 34).”
BackgroundCosenza, M., Sacchi, S., & Pozzi, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147652 · Cited by 147
“During T-cell therapies, CRS occurs early during the course of treatment [76].”
BackgroundMethodMichels, K. R., Sheih, A., Hernández, S., Brandes, A., Parrilla, D., Irwin, B., Perez, A. M., Ting, H.-A., Nicolai, C. J., Gervascio, T., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006292 · Cited by 146
Rabilloud, T., Potier, D., Pankaew, S., Nozais, M., Loosveld, M., & Payet‐Bornet, D. (2021) · Nature Communications · doi:10.1038/s41467-021-21168-6 · Cited by 141
CAR‐NK cells: the next wave of cellular therapy for cancer
Daher, M., Garcia, L. M., Li, Y., & Rezvani, K. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1274 · Cited by 136
“Tisagenlecleucel was shown to be effective in children and young adults with B-ALL and adult patients with aggressive B-cell lymphomas.(5,6) Axicabtagene ciloleucel is approved for the treatment of patients with relapsed or refractory aggressive B-cell lymphomas.”
BackgroundLeahy, A. B., Newman, H. M., Li, Y., Liu, H., Myers, R. M., DiNofia, A. M., Dolan, J. G., Callahan, C. A., Baniewicz, D., Devine, K. J., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00238-6 · Cited by 139
Self-citationHarnessing the chemokine system to home CAR-T cells into solid tumors
Foeng, J., Comerford, I., & McColl, S. R. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100543 · Cited by 169
Mabe, N. W., Huang, M., Dalton, G. N., Alexe, G., Schaefer, D. A., Geraghty, A. C., Robichaud, A. L., Conway, A. S., Khalid, D., Mader, M. M.-D., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00405-x · Cited by 150
Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input
Wang, V., Gauthier, M., Decot, V., Reppel, L., & Bensoussan, D. (2023) · Cancers · doi:10.3390/cancers15041003 · Cited by 124
“The Czech Republic, Switzerland, Russia, and France have each investigated two studies.”
InfluentialSarkar, R. R., Gloude, N. J., Schiff, D. E., & Murphy, J. D. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy193 · Cited by 132
“(11) found an 81% remission rate and 76% overall”
BackgroundMethodResultInfluentialEfficacy and Safety of CD28- or 4-1BB-Based CD19 CAR-T Cells in B Cell Acute Lymphoblastic Leukemia
Zhao, X., Yang, J., Zhang, X., Lu, X., Xiong, M., Zhang, J., Zhou, X., Qi, F., He, T., Ding, Y., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.06.016 · Cited by 146
“Besides pre-clinical studies, previous case series have revealed that BALL patients receiving 4-1BB-based CD19 CAR-T cells achieve 83%– 93% CR, while the CR of patients treated with CD28 CAR-T cells is lower (70%–88%).(6,7,11,25,26) It seems that 4-1BB is more applicable as a component of CAR compared with CD28 after…”
BackgroundResultKatsarou, A., Sjöstrand, M., Naik, J., Mansilla-Soto, J., Kefala, D., Kladis, G., Nianias, A., Ruiter, R., Poels, R., Sarkar, I., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abh1962 · Cited by 131
“Second-generation CARs that provide combined activation and costimulatory signals (1) have been shown to induce impressive clinical responses when targeting CD19 and have been approved for medical use in chemotherapy-resistant B cell leukemias and lymphomas (2, 3).”
BackgroundInsights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy
Gauthier, J., & Turtle, C. J. (2018) · Current Research in Translational Medicine · doi:10.1016/j.retram.2018.03.003 · Cited by 147
“The incidence of neurotoxicity, defined as any neurological symptoms occurring after CART cells in the absence of another cause, also varies across studies, ranging from 13% [4] to 63% [7] in ALL, and from 7% [10] to 31% [12] in NHL.”
BackgroundLee, Y. G., Marks, I. S., Srinivasarao, M., Kanduluru, A. K., Mahalingam, S. M., Liu, X., Chu, H., & Low, P. S. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1834 · Cited by 144
“Then, when tumors reached approximately 100 mm(3) in size, 10(7) antiFITC CAR T cells were intravenously injected into the mice followed by either (1) PBS, (2) FITC-DUPA alone, (3) FITC-AZA alone, or (4) a cocktail of FITC-DUPA and FITC-AZA.”
MethodLiu, S., Deng, B., Yin, Z., Lin, Y., An, L., Liu, D., Pan, J., Yu, X., Chen, B., Wu, T., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26160 · Cited by 135
“Although CD19 CAR-T therapy has a dramatic effect on r/r B-ALL patients with high CR rates of 81–90%,(5-9) around 20–50% of patients relapsed at 6 months.(5,7,9) To overcome the drawback of single-target CAR-T treatment, the combination of both CD19 and CD22 CAR-T therapy has been conducted by a few groups, which incl…”
BackgroundYoshikawa, T., Wu, Z., Inoue, S., Kasuya, H., Matsushita, H., Takahashi, Y., Kuroda, H., Hosoda, W., Suzuki, S., & Kagoya, Y. (2021) · Blood · doi:10.1182/blood.2021012714 · Cited by 145
Forsberg, E. M. V., Lindberg, M. F., Jespersen, H., Alsén, S., Bagge, R. O., Donia, M., Svane, I. M., Nilsson, O., Ny, L., Nilsson, L. M., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3158 · Cited by 138
Recent progress in the treatment of cancer in children
Butler, E. B., Ludwig, K. F., Pacenta, H. L., Klesse, L. J., Watt, T. C., & Laetsch, T. W. (2021) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21665 · Cited by 156
Self-citationOverview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice
Sengsayadeth, S. M., Savani, B. N., Oluwole, O. O., & Dholaria, B. (2021) · eJHaem · doi:10.1002/jha2.338 · Cited by 143
“Subsequently, CAR-T cells are expanded ex vivo to produce a CAR-T product that is infused in patients with relapsed or refractory (R/R) high grade hematologic malignancies such as NHLs, B-ALL, and mantle cell lymphoma (MCL).”
BackgroundInfluentialTelomerase-Targeted Cancer Immunotherapy
Mizukoshi, E., & Kaneko, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081823 · Cited by 120
The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells
Bachmann, M. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.05.003 · Cited by 129
Immunotherapy in pediatric acute lymphoblastic leukemia
Inaba, H., & Pui, C. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09834-0 · Cited by 170
Lenk, L., Alsadeq, A., & Schewe, D. M. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09848-z · Cited by 137
Subklewe, M. S. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020001792 · Cited by 138
“Seven cases had product-related issues.(7) However, in the pivotal ZUMA-1 trial, the manufacture of axi-cel failed for only 1 of 111 patients.”
BackgroundPrecision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms
Michels, A., Ho, N., & Buchholz, C. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.05.018 · Cited by 140
“effect in treated patients.(11) Recently, two additional products, Tecartus and Abecma, have received regulatory approval, the latter extending indications for CAR therapy to multiple myeloma via B cell maturation antigen (BCMA).”
BackgroundOncolytic virus-derived type I interferon restricts CAR T cell therapy
Evgin, L., Huff, A. L., Wongthida, P., Thompson, J., Kottke, T., Tonne, J., Schuelke, M., Ayasoufi, K., Driscoll, C. B., Shim, K. G., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17011-z · Cited by 128
Chow, V. A., Shadman, M., & Gopal, A. K. (2018) · Blood · doi:10.1182/blood-2018-04-839217 · Cited by 128
Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers
Kailayangiri, S., Altvater, B., Wiebel, M., Jamitzky, S., & Rössig, C. (2020) · Cancers · doi:10.3390/cancers12051075 · Cited by 137
“Although CAR T cell recognition of CD19 is characterized by a very low detection threshold, requiring less than 100 antigens per cell [38], CD19-negative subpopulations can escape recognition, grow out, and produce relapses of the disease [11,13,19,39–41].”
BackgroundInfluentialCui, Q., Qian, C., Xu, N., Kang, L., Dai, H., Cui, W., Song, B., Yin, J., Li, Z., Zhu, X., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01092-4 · Cited by 135
“therapeutic approaches for those with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) [3, 4].”
BackgroundSingle-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission
Bai, Z., Feng, B., McClory, S., de Oliveira, B. C., Diorio, C. J., Grégoire, C., Tao, B., Yang, L., Zhao, Z., Peng, L., et al. (2024) · Nature · doi:10.1038/s41586-024-07762-w · Cited by 139
“During the initial phase of infusion (day 1–5), no notable difference was observed, probably attributable to the transient decrease in circulating CTL019 cells resulting from their dispersion throughout the peripheral blood, bone marrow and other tissues 30,31 .”
Self-citationEZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells
Kailayangiri, S., Altvater, B., Lesch, S., Balbach, S. T., Göttlich, C., Kühnemundt, J., Mikesch, J., Schelhaas, S., Jamitzky, S., Meltzer, J., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.014 · Cited by 131
Gupta, S., Seethapathy, H. S., Strohbehn, I. A., Frigault, M. J., O’Donnell, E., Jacobson, C. A., Motwani, S. S., Parikh, S. M., Curhan, G. C., Reynolds, K. L., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.10.011 · Cited by 130
Reactions Related to CAR-T Cell Therapy
Miao, L., Zhang, Z., Ren, Z., & Li, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663201 · Cited by 138
“These patients mostly undergo treatment in intensive care unit (ICU), which may increase the risk of nosocomial infections (31, 99); (b) Longterm and high-dose use of glucocorticoids for treatment of severe CRS and/or CRES can reduce the patient’s immunity (31, 38); (c) CD19-CAR-T cel ls can cause B-cel l dysplas ia a…”
BackgroundInfluentialCombination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
Yu, C., Liu, X., Yang, J., Zhang, M., Jin, H., Ma, X., & Shi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00990 · Cited by 126
“However, grade 3/4 adverse effects occurred in 73% patients, mainly the cytokine release syndrome (CRS) and neurotoxicity (100).”
BackgroundXu, Y., Yang, Z., Horan, L. H., Zhang, P., Liu, L., Zimdahl, B., Green, S., Lu, J., Morales, J. F., Barrett, D. M., et al. (2018) · Cell Discovery · doi:10.1038/s41421-018-0066-6 · Cited by 120
Self-citationCD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs
Zapata, J. M., Pérez-Chacón, G., Carr-Baena, P., Martínez‐Forero, I., Azpilikueta, A., Otano, I., & Melero, I. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02618 · Cited by 128
“Remarkably, it has been recently demonstrated the clinical effectiveness of this therapy in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (120, 121).”
BackgroundIngegnere, T., Mariotti, F. R., Pelosi, A., Quintarelli, C., De Angelis, B., Tumino, N., Besi, F., Cantoni, C., Locatelli, F., Vacca, P., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00957 · Cited by 122
Immune cell therapy for hepatocellular carcinoma
Mizukoshi, E., & Kaneko, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0742-5 · Cited by 134
“Moreover, in a global, multi-center trial for recurrent and refractory ALL including 75 patients, 81% achieved remission [78].”
BackgroundBorn to survive: how cancer cells resist CAR T cell therapy
Lemoine, J., Ruella, M., & Houot, R. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01209-9 · Cited by 144
“Mutations Flow cytometry analysis of 17 samples from pediatric and young-adult patients with R/R B-ALL showed that 12 patients had CD19-negative disease [7].”
BackgroundCaruso, S., Angelis, B. D., Bufalo, F. D., Ciccone, R., Donsante, S., Volpe, G., Manni, S., Guercio, M., Pezzella, M., Iaffaldano, L., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01376-3 · Cited by 130
“Moreover, in the setting of r/r AML patients, previous treatment with high-intensity chemotherapy regimens and significant contamination of leukaemia blasts in peripheral blood (PB) could lead to a poor quality of the autologous apheresis product, affecting the success rate of the manufacturing process [16].”
BackgroundAddressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments
Salzman, R., Cook, F., Hunt, T. D., Malech, H. L., Reilly, P. R., Foss-Campbell, B., & Barrett, D. M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.017 · Cited by 139
“Patients like Carly, who received Luxturna in clinical trials, may not achieve perfect vision after treatment, but Carly has a vastly improved quality of life since treatment.(8)”
BackgroundCooperative CAR targeting to selectively eliminate AML and minimize escape
Haubner, S., Mansilla‐Soto, J., Nataraj, S. E., Kogel, F., Chang, Q., de Stanchina, E., Lopez, M. A., Ng, M. R., Fraser, K. A., Subklewe, M., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.09.010 · Cited by 135
Köhl, U., Arsenieva, S., Holzinger, A., & Abken, H. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.254 · Cited by 122
“17–19 Discussion of the trial data is even more complex, since a number of technical variations and modifi-cations of the CAR design make direct comparisons of clinical efficacy almost impossible.”
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites
Titov, A., Petukhov, A., Staliarova, A., Motorin, D., Bulatov, E., Shuvalov, O. Y., Soond, S. M., Piacentini, M., Melino, G., Zaritskey, A. Y., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0918-x · Cited by 134
Blueprint for cancer research: Critical gaps and opportunities
Elmore, L. W., Greer, S. F., Daniels, E. C., Saxe, C. C., Melner, M. H., Krawiec, G. M., Cance, W. G., & Phelps, W. C. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21652 · Cited by 157
CAR T-cell therapy for B-cell lymphoma
Denlinger, N., Bond, D. A., & Jaglowski, S. M. (2021) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2021.100826 · Cited by 135
Immunotherapy of Neuroblastoma: Facts and Hopes
Anderson, J., Majzner, R. G., & Sondel, P. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1356 · Cited by 142
“The cancer immunotherapy revolution is exemplified by the outstanding success of checkpoint inhibitors in melanoma (1) and certain adult carcinomas (2) and chimeric antigen receptor T (CAR-T) cells in both adult and pediatric hematologic malignancies (3, 4).”
Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
Gajra, A., Zalenski, A., Sannareddy, A., Jeune-Smith, Y., Kapinos, K., & Kansagra, A. (2022) · Pharmaceutical Medicine · doi:10.1007/s40290-022-00428-w · Cited by 116
“In 2017, the US Food and Drug Administration (FDA) approved the first chimeric antigen receptor T-cell (CAR-T)mediated therapies for relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and r/r acute lymphoblastic leukemia (ALL) [1, 2].”
BackgroundInfluentialBreast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells
Maulana, T. I., Teufel, C., Cipriano, M., Roosz, J., Lazarevski, L., van den Hil, F. E., Scheller, L., Orlova, V. V., Koch, A., Hudecek, M., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.04.018 · Cited by 137
Antibody and antibody fragments for cancer immunotherapy
Chen, W., Yang, Y., & Jiang, X. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.021 · Cited by 129
Gottschlich, A., Thomas, M., Grünmeier, R., Lesch, S., Rohrbacher, L., Igl, V., Briukhovetska, D., Benmebarek, M.-R., Vick, B., Dede, S., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01684-0 · Cited by 139
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades
Jabbour, E. J., Short, N. J., Jain, N., Haddad, F., Welch, M. A., Ravandi, F., & Kantarjian, H. M. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01409-5 · Cited by 132
“Currently, two CD19-directed CAR T cell products are approved for the management of ALL, tisagenlecleucel (Salvage 2 +; age < 26 years) and brexucabtagene autoleucel (R/R disease irrespective of salvage status; age ≥ 18 years) [126, 127].”
BackgroundAwasthi, R., Maier, H. J., Zhang, J., & Lim, S. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2210046 · Cited by 123
“Following bridging chemotherapy, patients with more than 10(3) cells/mm(3) of white cell count within 1 week before tisagenlecleucel infusion received lymphodepletion chemotherapy containing fludarabine-cyclophosphamide or bendamustine in DLBCL patients(6) or fludarabinecyclophosphamide or cytarabine-etoposide in ALL…”
MethodHassan, R., Butler, M. O., O'Cearbhaill, R. E., Oh, D. Y., Johnson, M. L., Zikaras, K., Smalley, M., Ross, M. G., Tanyi, J. L., Ghafoor, A., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02452-y · Cited by 132
Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy
Fabrizio, V. A., Boelens, J. J., Mauguen, A., Baggott, C., Prabhu, S., Egeler, E. L., Mavroukakis, S. A., Pacenta, H. L., Phillips, C. L., Rossoff, J. E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021006418 · Cited by 136
Self-citationImmunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation
Khan, A. N., Chowdhury, A., Karulkar, A., Jaiswal, A. K., Banik, A., Asija, S., & Purwar, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.886546 · Cited by 135
Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
Foà, R., & Chiaretti, S. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2113347 · Cited by 130
Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma
Caimi, P. F., Pacheco Sanchez, G., Sharma, A., Otegbeye, F., Ahmed, N., Rojas, P., Patel, S., Kleinsorge Block, S., Schiavone, J., Zamborsky, K., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.745320 · Cited by 121
Brown, P. A., Pieters, R., & Biondi, A. (2018) · Blood · doi:10.1182/blood-2018-04-785980 · Cited by 129
Rafei, H., Daher, M., & Rezvani, K. (2020) · British Journal of Haematology · doi:10.1111/bjh.17186 · Cited by 127
Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
Sterner, R. C., & Sterner, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.879608 · Cited by 138
“CAR-T cells have caused significant morbidity and mortality via these three main toxicity syndromes (8, 9, 18, 19).”
BackgroundLontos, K., Wang, Y., Joshi, S. K., Frisch, A. T., Watson, M. J., Kumar, A., Menk, A. V., Wang, Y., Cumberland, R. L., Lohmueller, J. J., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006522 · Cited by 136
Müller, S., Bexte, T., Gebel, V., Kalensee, F., Stolzenberg, E., Hartmann, J., Koehl, U., Schambach, A., Wels, W. S., Modlich, U., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03123 · Cited by 115
A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia
Martino, M. V., Alati, C., Canale, F. A., Musuraca, G., Martinelli, G., & Cerchione, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042150 · Cited by 134
“The same group designed a nonrandomized Tisacel therapy study (ELIANA trial), using a global supply chain and 25 study sites in 11 countries across North America, Europe, Asia, and Australia [37].”
Li, L., Mohanty, V., Dou, J., Huang, Y., Banerjee, P. P., Miao, Q., Lohr, J. G., Vijaykumar, T., Frede, J., Knoechel, B., et al. (2023) · Science Advances · doi:10.1126/sciadv.add6997 · Cited by 115
Shi, M., Wang, J., Huang, H., Liu, D., Cheng, H., Wang, X., Chen, W., Yan, Z., Sang, W., Qi, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47801-8 · Cited by 138
T-cell agonists in cancer immunotherapy
Choi, Y., Shi, Y., Haymaker, C. L., Naing, A., Ciliberto, G., & Hajjar, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000966 · Cited by 119
“44 45 Several studies have combined targeting 4-1BB with chimeric antigen receptor T-cell therapy.”
BackgroundSmith, E. L., Staehr, M., Masakayan, R., Tatake, I. J., Purdon, T. J., Wang, X., Wang, P., Liu, H., Xu, Y., Garrett-Thomson, S. C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.03.016 · Cited by 118
Metadata
- Authors
- Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K. L., Martin, P. L., Nemecek, E. R., Yanik, G. A., Peters, C., Baruchel, A., Boissel, N., Mechinaud, F., Balduzzi, A., Krueger, J., June, C. H., Levine, B. L., Wood, P., Taran, T., Leung, M., Mueller, K. T., Zhang, Y., Sen, K., Lebwohl, D., Pulsipher, M. A., & Grupp, S. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Oslo University Hospital (NO)
- Hospital Sant Joan de Déu Barcelona (ES)
- University of Minnesota (US)
- Children's Mercy Hospital (US)
- From the Departments of Pediatrics (S.L.M., S.A.G.) and Pathology and Laboratory Medicine (C.H.J., B.L.L.), Perelman School of Medicine, and Abramson Cancer Center (C.H.J., B.L.L.), University of Pennsylvania, and the Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia (S.L.M., S.A.G.) — all in Philadelphia; the Department of Pediatrics and Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern...
- Royal Children's Hospital (AU)
- University of Southern California (US)
- ORCID
- Maude, Shannon L.
- Laetsch, Theodore W.
- Buechner, Jochen
- Rives, Susana
- Boyer, Michael
- Bittencourt, Henrique
- Bader, Peter
- Verneris, Michael R.
- Stefanski, Heather E.
- Qayed, Muna
- Hiramatsu, Hidefumi
- Davis, Kara L.
- Martin, Paul L.
- Nemecek, Eneida R.
- Yanik, Gregory A.
- Peters, Christina
- Boissel, Nicolas
- Mechinaud, Francoise
- Balduzzi, Adriana
- Krueger, Joerg
- June, Carl H.
- Levine, Bruce L.
- Zhang, Yiyun
- Lebwohl, David
- Pulsipher, Michael A.
- Grupp, Stephan A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02
- Volume
- 378
- Issue
- 5
- Pages
- 439-448
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5996391
- OpenAlex
- W2787301955
- Cited by
- 5,735
- References
- 24
- Citations by year
- 2026: 573 · 2025: 671 · 2024: 734 · 2023: 730 · 2022: 784 · 2021: 788 · 2020: 706 · 2019: 496 · 2018: 242
- FWCI
- 207.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tisagenlecleucel, CAR T-cell therapy, anti-CD19, B-cell acute lymphoblastic leukemia, relapsed/refractory leukemia, pediatric and young adult patients, complete remission, minimal residual disease, event-free survival, overall survival, cytokine release syndrome, neurological adverse events, CAR T cell persistence, tocilizumab, treatment toxicity
- MeSH terms
- Adolescent, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Female, Humans, Infusions, Intravenous, Male, Receptors, Antigen, T-Cell, Remission Induction, Survival Analysis, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.